Jazz Pharmaceuticals Raises 2026 Revenue Outlook to $4.775B-$4.85B
The company reported third-quarter Xywav sales up 12% year over year and Zepzelca sales up 32%, partly offset by declines in Epidiolex and Xyrem. Gross-margin guidance remains 89%-90%, with a GAAP tax rate forecast of 20%-30%.
Jazz Pharmaceuticals has raised its 2026 revenue outlook to between $4.775 billion and $4.85 billion. The company reported that third-quarter sales for its Xywav sleep medication grew 12% year over year, while its Zepzelca oncology treatment saw a 32% increase. These gains were partially offset by declines in Epidiolex and Xyrem sales. The company maintained its gross-margin guidance of 89%—90% and expects a GAAP tax rate between 20% and 30%.